Pharma Two B Ltd.: Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease
Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a marketed
Source: finanznachrichten.de